SYBX (Synlogic) Short-Term Debt to Capital

Corporate company logo of Synlogic Inc. (SYBX)

This daily price chart for Synlogic, Inc. (SYBX) on the GURU.Markets platform shows the metric at 0.00. Synlogic, Inc. (SYBX) develops synthetic treatments for metabolic pathologies, mitigating risks through alliances with industry behemoths. The business targets patients with rare diagnoses, relying on insurance reimbursement for costs. Following a rigorous reorganization, the firm seeks a strategic partner to maintain liquidity and ensure survival.

Ratio of Short-Term Indebtedness to Capital: synlogictx.com (SYBX) for 07/04/2022 - 01/24/2026

Analytical breakdowns for Synlogic, Inc.

- stock quotes and analyst forecast:
Stock Price Synlogic, Inc.|SYBX - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Synlogic Inc.|SYBX - Enterprise Value
- book capitalization information:
Net Assets per Single Share Synlogic|SYBX - Accounting Value of Company|Market Value to Book Value Ratio synlogictx.com|SYBX - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Synlogic, Inc.|SYBX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Synlogic, Inc.|SYBX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Synlogic Inc.|SYBX - Company Long-Term Liabilities|Company Short-Term Debts Synlogic|Quick Liquidity Indicator synlogictx.com
- company profitability and valuation multiples indicators:
SYBX - Profit After Payment of Taxes
Fundamental valuation:SYBX Synlogic
Brand item of synlogictx.com

For Synlogic, Inc., which develops biologics through strategic alliances, the short-term debt-to-equity ratio on GURU.Markets reflects the balance between operational autonomy and credit burden. The ratio of liabilities with a maturity of up to one year to shareholders' equity determines the business's degree of dependence on external financing, where low values confirm liquidity but may signal a conservative approach to scaling R&D projects.

Competitors of Synlogic, Inc.

Short-Term Debt to Capital ASND|MDGL (Madrigal Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CORT (Corcept Therapeutics)|Short-Term Debt to Capital rhythmtx.com RYTM|AKRO - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital MTSR (Metsera, Inc.)|MoonLake Pharma (MLTX) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Crinetics Corp|NAMS (NewAmsterdam Pharma) - Short-Term Debt to Capital|Short-Term Debt to Capital soleno.life|Short-Term Debt to Equity Ratio FOLD (Amicus Therapeutics, Inc.)|ETNB (89bio Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Agios Pharmaceuticals Inc AGIO|GPCR - Short-Term Debt to Equity Ratio|MiMedx Group, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital rezolutebio.com|LXRX (Lexicon Pharmaceuticals, Inc.) - Short-Term Debt to Equity Ratio|MBX: Short-Term Loans to Capital Ratio|ALT (Altimmune Corp) - Short-Term Debt to Capital|Short-Term Debt to Capital Aardvark Pharma|Short-Term Debt to Capital SGMT|Short-Term Debt to Equity BIOA (bioagelabs.com)|Short-Term Debt to Equity Biomea Fusion BMEA|Quince Therapeutics Inc (QNCX) - Current Liabilities to Capital|GUTS - Short-Term Debt to Equity|VTVT: Short-Term Debt to Equity|ATPC: Short-Term Debt to Capital|PLUR - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Lipocine|Matinas BioPharma Holdings Inc. (MTNB) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Spruce Biosciences (SPRB)|Short-Term Debt to Equity Ratio Galecto Corporation GLTO|Short-Term Debt to Equity Carmell Corporation CTCX|Short-Term Debt to Capital Coefficient lumos-pharma.com (LUMO)|ONVO: Short-Term Debt to Equity Ratio|Current Liabilities to Capital Radius Recycling Inc.